BeOne Medicines Ltd. (ONC)
358.07
-0.70
(-0.20%)
USD |
NASDAQ |
Oct 02, 16:00
357.99
-0.08
(-0.02%)
After-Hours: 20:00
BeOne Medicines Enterprise Value : 34.09B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 34.09B |
| October 01, 2026 | 34.16B |
| September 30, 2026 | 34.91B |
| September 29, 2026 | 34.84B |
| September 28, 2026 | 35.02B |
| September 25, 2026 | 34.38B |
| September 24, 2026 | 34.29B |
| September 23, 2026 | 34.81B |
| September 22, 2026 | 35.13B |
| September 21, 2026 | 34.88B |
| September 18, 2026 | 33.34B |
| September 17, 2026 | 33.61B |
| September 16, 2026 | 33.05B |
| September 15, 2026 | 32.89B |
| September 14, 2026 | 33.65B |
| September 11, 2026 | 32.89B |
| September 10, 2026 | 32.40B |
| September 09, 2026 | 33.35B |
| September 08, 2026 | 33.40B |
| September 04, 2026 | 34.11B |
| September 03, 2026 | 34.57B |
| September 02, 2026 | 34.48B |
| September 01, 2026 | 34.15B |
| August 31, 2026 | 34.25B |
| August 28, 2026 | 34.99B |
| Date | Value |
|---|---|
| August 27, 2026 | 35.59B |
| August 26, 2026 | 35.94B |
| August 25, 2026 | 36.00B |
| August 24, 2026 | 35.54B |
| August 21, 2026 | 35.80B |
| August 20, 2026 | 35.25B |
| August 19, 2026 | 36.05B |
| August 18, 2026 | 35.25B |
| August 17, 2026 | 34.55B |
| August 14, 2026 | 32.99B |
| August 13, 2026 | 33.88B |
| August 12, 2026 | 34.19B |
| August 11, 2026 | 34.22B |
| August 10, 2026 | 34.19B |
| August 07, 2026 | 33.07B |
| August 06, 2026 | 31.15B |
| August 05, 2026 | 30.91B |
| August 04, 2026 | 30.44B |
| August 03, 2026 | 29.48B |
| July 31, 2026 | 29.71B |
| July 30, 2026 | 30.34B |
| July 29, 2026 | 30.88B |
| July 28, 2026 | 31.21B |
| July 27, 2026 | 30.74B |
| July 24, 2026 | 30.74B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 159.91M |
| CRISPR Therapeutics AG | 3.777B |
| Idorsia Ltd. | 2.970B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 237.40M |
| Revenue (Quarterly) | 1.708B |
| Total Expenses (Quarterly) | 1.470B |
| EPS Diluted (Quarterly) | 2.050 |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | 13.90% |
| Earnings Yield | 1.59% |
| Operating Earnings Yield | 2.24% |
| Normalized Earnings Yield | 1.673 |